Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Fungal Keratitis Treatment Market

Fungal Keratitis Treatment Market Share

Report ID: GMI9024
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Fungal Keratitis Treatment Market Share

The fungal keratitis treatment industry is characterized by intense competition among key players striving to improve patient outcomes and address unmet medical needs in the management of this challenging eye condition. Some of the significant players Merck & Co. Inc., Pfizer, Inc., Glenmark Pharmaceuticals, and Alvogen are likely to hold significant market shares due to their extensive product portfolios and global reach.

Fungal Keratitis Treatment Market Companies

Prominent players operating in the fungal keratitis treatment industry include:

Alvogen
Aurolab
Bausch Health Companies Inc.
Eyevance Pharmaceuticals LLC
Gilead Biosciences, Inc.
Glenmark Pharmaceuticals Ltd.
Leadiant Biosciences, Inc.
Merck & Co. Inc.
Novo Holdings A/S (Xellia Pharmaceuticals)
Pfizer Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global fungal keratitis treatment market was valued at USD 875.4 million in 2023 and is anticipated to grow at 6.1% CAGR from 2024 – 2032, attributed to increasing incidence of eye infections and growing geriatric population.

The geriatric segment in the fungal keratitis treatment industry is anticipated to reach USD 711.2 million by 2032, due to age-related changes in the immune system, ocular surface, and underlying medical conditions such as diabetes and immunosuppression.

North America fugal keratitis treatment market was valued at USD 353.7 million in 2023 and is anticipated to reach USD 585.6 million by 2032, owing to advanced healthcare infrastructure, high prevalence of risk factors and stringent regulatory framework.

Alvogen , Aurolab , Bausch Health Companies Inc., Eyevance Pharmaceuticals LLC , Gilead Biosciences, Inc. , Glenmark Pharmaceuticals Ltd., Leadiant Biosciences, Inc., Merck & Co. Inc., Novo Holdings A/S (Xellia Pharmaceuticals) and Pfizer Inc.